doranidazole has been researched along with Adenocarcinoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hosotani, R; Karasawa, K; Matsui, K; Matsuno, S; Nemoto, K; Nishimura, Y; Ogata, Y; Okamoto, A; Sunamura, M | 1 |
1 trial(s) available for doranidazole and Adenocarcinoma
| Article | Year |
|---|---|
Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Humans; Imidazoles; Intraoperative Period; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis | 2004 |